The Escalating Challenges of Gram-Resistant Organisms: The Role of Cefiderocol
August 18th 2025Clinical trial and real-world data, including the PROVE study, support its role as an effective and carbapenem-sparing therapy for serious infections, though outcomes vary depending on pathogen and infection type.
A Holistic Approach to HIV Patient Care
August 18th 2025In the second episode of Allegheny Health Network’s (AHN) Media Day, Cassandra Oehler, MD, provides insights on HIV care at AHN's Positive Health Clinic (PHC), including the comprehensive services they offer and how they are involved in clinical trials using long-acting injectables.
Statistical Weighting Helps Reduce Bias in Observational Studies
August 15th 2025Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses the usage of inverse probability weighting with propensity scores to balance patient groups and limit bias.
Finding a Standard Course of Treatment for Bartonella Infections
August 11th 2025Emily Olsen, PhD, offers some insights on this underdiagnosed infection, including describing antimicrobial studies, particularly in biofilm and intracellular environments. Her findings look to create a standardized approach for treating all forms of the different presentations of bartonellosis.
FDA Lifts Pause on Chikungunya Vaccine IXCHIQ Use in Adults 60+ Following Safety Review
Published: August 8th 2025 | Updated: August 8th 2025After a three-month review, the FDA and EMA have cleared continued use of IXCHIQ in adults 60+, adding new safety warnings for elderly individuals with chronic conditions.
Determining Resistance Patterns in Difficult-to-Treat Resistant Pseudomonas Infections
August 5th 2025Results from a recent study comparing ceftolozane-tazobactam and ceftazidime-avibactam for difficult-to-treat Pseudomonas aeruginosa infections found no statistically significant difference in resistance emergence but a surprising numerical trend favoring ceftazidime-avibactam. Pranita Tamma, MD, MHS, continues her conversation about this topic.